Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (281-290 of 436) with videos related to

Pageof 44
Sort By:
Blood Advances|January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosisPrajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
American Journal of Hematology|September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesDaniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
JCO Precision Oncology|May 17, 2023
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class RearrangementsJayastu Senapati, Elias Jabbour, Marina Konopleva, et al.
Haematologica|September 2, 2017
Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patientsNitin Jain, Xinyan Lu, Naval Daver, et al.
The Lancet. Haematology|July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trialTapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Blood Cancer Journal|May 21, 2025
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Haematologica|July 22, 2017
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndromeNaval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
Pageof 44

Showing results (281-290 of 436) with videos related to

Sort By:
Pageof 44
Blood Advances|January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosisPrajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
American Journal of Hematology|September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesDaniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
JCO Precision Oncology|May 17, 2023
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class RearrangementsJayastu Senapati, Elias Jabbour, Marina Konopleva, et al.
Haematologica|September 2, 2017
Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patientsNitin Jain, Xinyan Lu, Naval Daver, et al.
The Lancet. Haematology|July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trialTapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Blood Cancer Journal|May 21, 2025
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Haematologica|July 22, 2017
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndromeNaval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
Pageof 44